One main mechanism underlying PDLIM2 suppression of lung cancer development and therapeutic resistance involves repressing STAT3-dependent transcriptional repression of MHC-I and subsequent tumor immune evasion in the presence or absence of anti-PD-1 and chemotherapeutic drugs. This evidence concerns the gene PDLIM2 and lung carcinoma.